This week we look at how financial interests can influence researchers, real time data in healthcare, insights into physician DTC views, the needed collaboration between doctors and drug companies and the impact of lower-cost drugs:
– A new report, though focused specifically on medical journals, reminds us to maintain a healthy level of skepticism when interpreting any study’s findings. How Much Do Financial Interests Sway Researchers? from Pacific Standard reminds us that doctors and researchers should wait for second and third studies backing up the first before moving forward with a new treatment – and then “remain vigilant” for any worrisome findings that may come later
– Perhaps nowhere is data – especially real-time data – more useful than in healthcare, where firms can take information and channel it into instant results, helping them give each individual patient the care that they deserve. Real Time Data Has Lasting Impact on Healthcare Industry from Experian suggests a few specific ways that real time data can improve medical care
– World of DTC Marketing’s Insights Into the Research With Physicians on DTC Advertising covers key findings and offers insights from the CMI Compas Study research with physicians on direct-to-consumer advertising. This study could possibly serve as leading indicators for what’s to come from the upcoming FDA study focusing on physicians and other healthcare professionals to understand the effect that DTC pharmaceutical advertising has on their prescribers’ behaviors
– There is a way to cultivate, not demonize, collaboration between physicians and pharma. The Atlantic’s Getting to the Right Relationship Between Doctors and Drug Companies concludes the key issue is interdependence. Like digital health, drug development is far too important, and far too difficult, for anyone to do by themselves
– Medical Marketing and Media’s Studies Show Cheaper Drugs Don’t Add Up To Greater Use reveals that while the patent cliff is credited with creating a deep pool of low-cost versions of breakthrough drugs, a pair of reports suggests that framing these shifts in IP protections as a cost-savings for patients is an incomplete picture of just what’s going on in terms of patient health
That wraps this week’s review of news from and for the pharma market research community. I’ll leave you with an invitation to learn more about the benefits of real time data and offer you a personal demo of InCrowd’s on-demand platform providing you direct and immediate access to Crowds of screened and targeted healthcare professionals.
If you have tips, suggestions or resources you’d like to share leave us a comment below and please feel free to suggest topics that you’d like to see covered in future posts.
